Sandostatin
Gastrointestinal Neuroendocrine Pancreatic Tumor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
40 Active assets in the Gastrointestinal Neuroendocrine Pancreatic Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxodotreotide University of Chicago | Phase 4 | BBB |
Everolimus Exelixis | Phase 4 | BBB |
Irinotecan M.D. Anderson Cancer Center | Phase 2/3 | BB |
Oxodotreotide National Cancer Institute (NCI) | Phase 4 | BB |
Octreotide Pamoate RayzeBio, Inc. | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Sandostatin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →